ReviewJournal of enzyme inhibition and medicinal chemistry2026
Nanozymes: bridging nanoscale characteristics and catalytic mechanisms for advanced biomedical applications.
Review in Journal of enzyme inhibition and medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nanozymes-nanomaterials with intrinsic enzyme-like activity-have emerged as a transformative paradigm in biomedicine. Their catalytic proficiency is fundamentally dictated by unique nanoscale characteristics, particularly tuneable surface defects and geometric configurations. This review critically re-evaluates nanozyme catalytic mechanisms, precisely categorising them into reactive oxygen species (ROS)-generating pathways and electron-transfer processes. We highlight recent structural breakthroughs, emphasising the evolution from conventional nanoparticles to single-atom and dual-atom nanozymes (SANs/DANs) that exhibit unprecedented reaction kinetics. Furthermore, we synthesise their advanced applications across in vitro diagnostics, synergistic tumour therapy, antibacterial interventions, and regenerative medicine. Finally, we address current clinical translational bottlenecks and envision how artificial intelligence (AI)-guided rational design will shape the field's future. By bridging fundamental physical chemistry with clinical utility, this review provides a definitive mechanistic roadmap for deploying nanozymes in precision nanomedicine.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.